awmsg logo



afamelanotide (Scenesse®)


Reference No. 634

Publication date:
23/03/2018


Appraisal information

afamelanotide (Scenesse®) 16 mg subcutaneous implant


Company: Clinuvel Pharmaceuticals Ltd
BNF category: Skin
NMG meeting date: 03/05/2017
AWMSG meeting date: 13/09/2017
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1717
Ratification by Welsh Government: 22/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (ID927) NICE GUIDANCE ISSUED MAY 2018 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download